

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 April 2024 (11.04.2024)



(10) International Publication Number
WO 2024/077140 A1

(51) International Patent Classification:

C12N 5/00 (2006.01) A61P 7/00 (2006.01)
A61K 35/545 (2015.01) C07K 14/705 (2006.01)
A61P 35/00 (2006.01) C12N 15/113 (2010.01)

(21) International Application Number:

PCT/US2023/076083

(22) International Filing Date:

05 October 2023 (05.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/413,331 05 October 2022 (05.10.2022) US

(71) Applicant: GARUDA THERAPEUTICS, INC. [US/US];

215 First St., Suites 340-350, Cambridge, MA 02142 (US).


(72) Inventor: **SHAH, Dhvanit**; c/o Garuda Therapeutics, Inc,
215 First St., Suites 340-350, Cambridge, MA 02142 (US).

(74) Agent: **HAYMAN, Mark, L.** et al.; Morgan, Lewis &
Bockius LLP, 1701 Market Street, Philadelphia, PA 19103
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: IMMUNE COMPATIBLE CELLS FOR ALLOGENEIC CELL THERAPIES TO COVER GLOBAL, ETHNIC, OR
DISEASE-SPECIFIC POPULATIONS

FIG. 2



(57) Abstract: In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specific populations. In the various aspects and embodiments, the cell banks and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the cell banks by gene editing, and methods for cell therapy involving cells or tissues derived from the cell banks (including but not limited to hematopoietic stem cells, or "HSCs", progenitors, or progenies thereof).

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*